Back to Trial

Oracle Runs

Oracle findings and outcome history for Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis (NCT05177835).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:50 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

The exact Phase 2 long-term maintenance study appears to have had a positive interim public readout. Abivax explicitly called it a “positive interim efficacy and safety analysis,” and Abivax had previously identified NCT05177835 as the merged Phase 2a/2b maintenance trial this readout describes.

Sources
Sponsorir.abivax.com10/3/24
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax announced results of a positive interim efficacy and safety analysis from an open-label maintenance study enrolling UC patients after the Phase 2a and Phase 2b OLM studies.

View source
Sponsorir.abivax.com1/6/22
Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval

Abivax said the Phase 2a and Phase 2b maintenance studies were merged into one single maintenance trial, NCT05177835.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted86% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

The exact Phase 2 long-term maintenance study appears to have had a positive interim public readout. Abivax explicitly called it a “positive interim efficacy and safety analysis,” and Abivax had previously identified NCT05177835 as the merged Phase 2a/2b maintenance trial this readout describes.

Found Apr 1, 2026, 7:50 PMOutcome date Oct 3, 2024, 6:30 AMReviewed Apr 1, 2026, 7:56 PM
Sponsorir.abivax.comOct 3, 2024, 6:30 AM
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax announced results of a positive interim efficacy and safety analysis from an open-label maintenance study enrolling UC patients after the Phase 2a and Phase 2b OLM studies.
Sponsorir.abivax.comJan 6, 2022, 12:00 AM
Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval
Abivax said the Phase 2a and Phase 2b maintenance studies were merged into one single maintenance trial, NCT05177835.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:56 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)86% confidenceReviewed Apr 1, 2026, 7:56 PM

The exact Phase 2 long-term maintenance study appears to have had a positive interim public readout. Abivax explicitly called it a “positive interim efficacy and safety analysis,” and Abivax had previously identified NCT05177835 as the merged Phase 2a/2b maintenance trial this readout describes.